Presage Biosciences
Biotechnology, 530 Fairview Ave N Ste 1000, Seattle, Washington, 98109, United States, 11-50 Employees
Phone Number: 80********
Who is PRESAGE BIOSCIENCES
What if you could test the efficacy of multiple new cancer drugs in a patient without harmful side effects? We asked this question when we started Presage to address a fundamental issue t...
Read More
- Headquarters: 530 Fairview Ave N Ste 1000, Seattle, Washington, 98109, United States
- Date Founded: 2008
- Employees: 11-50
- Revenue: $1 Million to $5 Million
- Active Tech Stack: See technologies
- CEO: Richard Klinghoffer
Industry: Biotechnology
SIC Code: 2834 | NAICS Code: 325412 | Show More
Does something look wrong? Fix it. | View contact records from PRESAGE BIOSCIENCES
Presage Biosciences Org Chart and Mapping
Similar Companies to Presage Biosciences
Athira Pharma
- 51-200
- $ 10 Million to 25 Million
Blaze Bioscience
- 11-50
- $ 10 Million to 25 Million
Day One Biopharmaceuticals
- 11-50
- $ 10 Million to 25 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Presage Biosciences
Answer: Presage Biosciences's headquarters are located at 530 Fairview Ave N Ste 1000, Seattle, Washington, 98109, United States
Answer: Presage Biosciences's phone number is 80********
Answer: Presage Biosciences's official website is https://presagebio.com
Answer: Presage Biosciences's revenue is $1 Million to $5 Million
Answer: Presage Biosciences's SIC: 2834
Answer: Presage Biosciences's NAICS: 325412
Answer: Presage Biosciences has 11-50 employees
Answer: Presage Biosciences is in Biotechnology
Answer: Presage Biosciences top competitors include: Athira Pharma , Blaze Bioscience , Day One Biopharmaceuticals
Answer: Presage Biosciences contact info: Phone number: 80******** Website: https://presagebio.com
Answer: What if you could test the efficacy of multiple new cancer drugs in a patient without harmful side effects? We asked this question when we started Presage to address a fundamental issue that hampers development of new cancer drugs. The issue as we see it is that new drugs are tested in laboratory models of cancer that simply do not accurately represent the complexity of the human tumor microenvironment and therefore do not reliably predict patient benefit in the clinic. As a result, drugs that exhibit outstanding performance in preclinical models of cancer more often than not, fail to provide benefit to patients when these same agents are tested in clinical trials. It's hard to deny this issue. The composite success rate for cancer drug candidates entering trials is a dismal 8%. This overwhelming percentage of clinical failures comes at tremendous cost to drug developers ($100s of millions to billions), and most importantly to patients in need of new therapy options. We can do better. Presage is addressing this issue with CIVO technology. CIVO enables, for the first time, simultaneous evaluation and comparison of multiple anti-cancer drugs, drug candidates, and drug combinations directly in a patients tumor, without toxicities associated with typical clinical drug exposures. This is done via a new way to approach Phase 0 clinical trials. Presage has established feasibility of CIVO in the clinic, a dedicated engineering and clinical operations team, a clear regulatory path, and a network of CIVO-trained clinical sites to execute on Phase 0 collaborations with biopharma partners. Presage has also established Phase 0 collaborations with marquee cancer drug development companies including Takeda, Celgene and Bristol-Myers Squibb. Our ultimate goal is to improve early drug evaluation and substantially increase the success rate of new drugs for cancer patients.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month